Aptamer Therapeutics for Complement Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic and diagnostic options for complement-related disorders, such as those involving the C5 protein, face limitations due to the immune response and administration challenges of antibody-based treatments.
Innovation Solution
Development of aptamers, specifically nucleic acid molecules with high specificity and affinity for the C5 protein, which can be administered subcutaneously and conjugated with PEG moieties to enhance stability and half-life, providing a novel approach for treating and diagnosing complement-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based treatments are used for complement-related disorders, then therapeutic efficacy is achieved, but immune response and administration challenges occur
Solution Approach 1:
The patent uses aptamers as simplified copies or alternatives to full antibodies. Aptamers are nucleic acid molecules that replicate the target-binding function of antibodies but with reduced immunogenicity and simplified structure, thereby maintaining therapeutic efficacy while reducing immune response issues
Solution Approach 2:
The patent employs aptamers which are chemically synthesized nucleic acid molecules with shorter half-lives compared to antibodies. These can be rapidly produced and administered as needed, providing a practical alternative that avoids the immunogenicity and complex production requirements of antibody-based therapies
2Ease of operation
If aptamers are administered subcutaneously, then administration convenience is improved, but bioavailability must be maintained
Solution Approach 1:
The patent modifies the physicochemical parameters of aptamers by conjugating them with PEG (polyethylene glycol) moieties. This PEGylation increases molecular size and hydrophilicity, improving solubility and enabling subcutaneous administration while maintaining adequate bioavailability through optimized pharmacokinetic properties
3Duration of action of stationary object
If aptamers are conjugated with PEG moieties, then stability and half-life are enhanced, but molecular size increases
Solution Approach 1:
The patent uses PEG moieties as intermediary molecules conjugated to aptamers. This PEGylation strategy acts as a mediator that extends circulation half-life and improves stability by reducing renal clearance and proteolytic degradation, while the flexible PEG chains minimize immunogenicity and maintain biodistribution properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Aptamers effectively inhibit C5 complement protein cleavage, offering a more stable, efficient, and less immunogenic alternative for treating and diagnosing complement-related disorders, including those associated with cardiac, inflammatory, and autoimmune conditions.
Implementation Method 1
Aptamers are nucleic acid molecules having specific binding affinity to molecules through interactions other than classic Watson-Crick base pairing
Implementation Method 2
conjugated with PEG moieties to enhance stability and half-life
Data Source
AI summary
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.